Treatment Trials

1 Clinical Trials for Various Conditions

Focus your search

      COMPLETED
      Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
      Description

      We will combine an oral investigational vascular endothelial growth factor (VEGF inhibitor) called pazopanib which is being studied in kidney cancer will be combined with standard chemotherapy called taxol in patients with relapsed recurrent urothelial cancer.

      Conditions
      Bladder CancerBladder (Urothelial, Transitional Cell) CancerBladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
      Talk to us